{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-26-000088","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2026-05-11T20:07:10+00:00","discovered_at":"2026-05-11T20:09:00.417903+00:00","generated_at":"2026-05-11T22:38:53.791401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial","bullets":["Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.","Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.","First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.","Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.","Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-26-000088","json":"https://secwatch.observer/filing/0001746473-26-000088.json","markdown":"https://secwatch.observer/filing/0001746473-26-000088.md","text":"https://secwatch.observer/filing/0001746473-26-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/0001746473-26-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/plrx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:38:53.791401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03b27417eab03e5e5de561cd650bdd92a3195f85","claim":"PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: net income Net loss was $20.0 million.","evidence_excerpt":"On May 11, 2026, Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/0001746473-26-000088-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $20.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}